Clinical Trial Update: A Fourteen-Week Placebo-Controlled Dose-Response Efficacy and Safety Study of NS 2330 in Early Parkinson's Disease Patients (Study for Proof of Concept in Early Parkinson's Disease of a Triple Reuptake Inhibitor, NS 2330 / SCEPTRE) [Phase 2]

View source ↗

Summary

A 14-week, placebo-controlled Phase 2 study to evaluate the efficacy and safety of NS 2330 (SCEPTRE) in early Parkinson disease as a proof-of-concept trial.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• NS 2330 (NS-2330)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Parkinson Disease | Phase 2 | Status: COMPLETED